TScan Therapeutics Income Statement (2020-2025) | TCRX

1Y3Y5Y7Y10YAll
Download Data
Income Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.29M0.80M2.03M2.85M2.41M2.85M3.02M4.06M3.36M3.10M5.80M3.15M3.89M7.21M0.57M0.54M1.05M0.67M2.17M3.08M2.51M
Operating items
Research & Development 5.81M5.96M7.34M10.80M14.21M12.61M14.69M14.49M15.03M15.60M21.78M21.23M22.74M22.41M24.86M26.88M26.26M29.35M29.79M32.63M31.69M
Selling, General & Administrative 1.65M2.64M2.61M2.73M4.05M4.45M4.49M4.81M4.91M6.14M7.77M6.53M5.89M6.16M7.08M7.77M7.41M8.02M8.63M9.10M7.87M
Operating Expenses 7.46M8.61M9.95M13.53M18.25M17.06M19.18M19.30M19.94M21.74M29.55M27.76M28.64M28.57M31.94M34.65M33.67M37.38M38.42M41.73M39.56M
Operating Income -7.17M-7.81M-7.92M-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M
EBIT -7.17M-7.81M-7.92M-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M
Non-operating items
Interest & Investment Income 0.00M0.00M0.01M0.01M0.00M0.00M0.01M0.15M0.53M0.90M1.14M1.53M2.73M2.60M2.19M3.40M3.69M2.78M2.80M2.39M2.04M
Other Non Operating Income 0.01M0.15M0.33M-0.07M0.18M0.56M1.75M1.74M1.23M2.45M2.73M0.90M2.12M1.70M1.34M
Non Operating Income 0.01M0.15M0.33M-0.07M0.18M0.56M1.75M1.74M1.23M2.45M2.73M0.90M2.12M1.70M1.34M
Net income details
EBT -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M
Profit After Tax -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.20M-15.10M-16.25M-18.72M-22.60M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-35.80M-34.13M-36.95M-35.71M
Income from Continuing Operations -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M
Consolidated Net Income -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M
Income towards Parent Company -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M
Net Income towards Common Stockholders -7.17M-7.81M-7.91M-10.67M-15.84M-14.20M-16.16M-15.10M-16.25M-18.72M-22.56M-24.05M-23.00M-19.61M-30.14M-31.66M-29.89M-34.72M-34.13M-36.95M-35.71M
Additional items
EPS (Basic) -7.16-8.08-6.49-7.69-0.800.38-0.67-0.63-0.67-0.77-0.93-0.51-0.24-0.11-0.32-0.28-0.25-0.31-0.26-0.28-0.28
EPS (Weighted Average and Diluted) -7.69-0.800.38-0.67-0.63-0.67-0.77-0.93-0.51-0.24-0.11-0.32-0.28-0.25-0.31-0.26-0.28-0.28
Shares Outstanding (Weighted Average) 1.00M0.92M1.22M1.39M19.88M11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M
Shares Outstanding (Diluted Average) 1.39M19.88M11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M
EBITDA -7.17M-7.81M-7.92M-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M
Interest Expenses 0.20M0.97M0.96M0.97M0.98M0.85M0.96M0.95M0.96M0.78M0.68M0.69M0.70M